Michael Pignone

Michael Pignone

Auto-generated profile, based on publicly available information

Michael Pignone

University of North Carolina, Chapel Hill, NC

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in The Annals of Family Medicine
Verified
Journal Article
Closed access
PDF file
BWBarry D. Weiss
Barry D. Weiss
MMMary Z. Mays
Mary Z. Mays
WMWilliam Martz
William Martz
KCKelley Merriam Castro
Kelley Merriam Castro
DDDarren A. DeWalt
Darren A. DeWalt
FHFrank A. Hale
Frank A. Hale
PURPOSE Current health literacy screening instruments for health care settings are either too long for routine use or available only in English. Our objective was to develop a quick and accurate screening test for limited literacy available in English and Spanish.

1 December 2004 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
DDDarren A. DeWalt
Darren A. DeWalt
NBNancy D. Berkman
Nancy D. Berkman
SSStacey Sheridan
Stacey Sheridan
KLKathleen N. Lohr
Kathleen N. Lohr
MPMichael P. Pignone
Michael P. Pignone

21 May 2002 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
MPMichael P. Pignone
Michael P. Pignone
BGBradley N. Gaynes
Bradley N. Gaynes
JRJerry L. Rushton
Jerry L. Rushton
CBCatherine Mills Burchell
Catherine Mills Burchell
COC. Tracy Orleans
C. Tracy Orleans
KLKathleen N. Lohr
Kathleen N. Lohr
To clarify whether screening adults for depression in primary care settings improves recognition, treatment, and clinical outcomes. The MEDLINE database was searched from 1994 through August 2001. Other relevant articles were located through other systematic reviews; focused searches of MEDLINE from 1966 to 1994; the Cochrane depression, anxiety, and neurosis database; hand searches of bibliographies; and extensive peer review. The researchers reviewed randomized trials conducted in primary care settings that examined the effect of screening for depression on identification, treatment, or health outcomes, including trials that tested integrated, systematic support for treatment after identification of depression. A single reviewer abstracted the relevant data from the included articles. A second reviewer checked the accuracy of the tables against the original articles. Compared with usual care, feedback of depression screening results to providers generally increased recognition of depressive illness in adults. Studies examining the effect of screening and feedback on treatment rates and clinical outcomes had mixed results. Many trials lacked power to detect clinically important differences in outcomes. Meta-analysis suggests that overall, screening and feedback reduced the risk for persistent depression (summary relative risk, 0.87 [95% CI, 0.79 to 0.95]). Programs that integrated interventions aimed at improving recognition and treatment of patients with depression and that incorporated quality improvements in clinic systems had stronger effects than programs of feedback alone. Compared with usual care, screening for depression can improve outcomes, particularly when screening is coupled with system changes that help ensure adequate treatment and follow-up.

2 January 2007 in Circulation
Verified
Journal Article
Closed access
JBJohn B. Buse
John B. Buse
HGHenry N. Ginsberg
Henry N. Ginsberg
GBGeorge L. Bakris
George L. Bakris
NCNathaniel G. Clark
Nathaniel G. Clark
FCFernando Costa
Fernando Costa
NSNeil J. Stone
Neil J. Stone
The American Heart Association (AHA) and the American Diabetes Association (ADA) have each published guidelines for cardiovascular disease prevention: The ADA has issued separate recommendations for each of the cardiovascular risk factors in patients with diabetes, and the AHA has shaped primary and secondary guidelines that extend to patients with diabetes. This statement will attempt to harmonize the recommendations of both organizations where possible but will recognize areas in which AHA and ADA recommendations differ.

15 January 2002 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
MHMichael Hayden
Michael Hayden
MPMichael Pignone
Michael Pignone
CPChristopher Phillips
Christopher Phillips
CMCynthia Mulrow
Cynthia Mulrow
The use of aspirin to prevent cardiovascular disease events in patients without a history of cardiovascular disease is controversial. To examine the benefits and harms of aspirin chemoprevention. MEDLINE (1966 to May 2001). 1] Randomized trials at least 1 year in duration that examined aspirin chemoprevention in patients without previously known cardiovascular disease and 2) systematic reviews, recent trials, and observational studies that examined rates of hemorrhagic strokes and gastrointestinal bleeding secondary to aspirin use. One reviewer read and extracted data from each included article and constructed evidence tables. A second reviewer checked the accuracy of the data extraction. Discrepancies were resolved by consensus. Meta-analysis was performed, and the quantitative results of the review were then used to model the consequences of treating patients with different levels of baseline risk for coronary heart disease. Five trials examined the effect of aspirin on cardiovascular events in patients with no previous cardiovascular disease. For patients similar to those enrolled in the trials, aspirin reduces the risk for the combined end point of nonfatal myocardial infarction and fatal coronary heart disease (summary odds ratio, 0.72 [95% CI, 0.60 to 0.87]). Aspirin increased the risk for hemorrhagic strokes (summary odds ratio, 1.4 [CI, 0.9 to 2.0]) and major gastrointestinal bleeding (summary odds ratio, 1.7 [CI, 1.4 to 2.1]). All-cause mortality (summary odds ratio, 0.93 [CI, 0.84 to 1.02]) was not significantly affected. For 1000 patients with a 5% risk for coronary heart disease events over 5 years, aspirin would prevent 6 to 20 myocardial infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bleeding events. For patients with a risk of 1% over 5 years, aspirin would prevent 1 to 4 myocardial infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bleeding events. The net benefit of aspirin increases with increasing cardiovascular risk. In the decision to use aspirin chemoprevention, the patient's cardiovascular risk and relative utility for the different clinical outcomes prevented or caused by aspirin use must be considered.

28 June 2004 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
MPMark J. Pletcher
Mark J. Pletcher
JTJeffrey A. Tice
Jeffrey A. Tice
MPMichael Pignone
Michael Pignone
WBWarren S. Browner
Warren S. Browner
Research from JAMA Internal Medicine — Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events — A Systematic Review and Meta-analysis